{"nctId":"NCT00382109","briefTitle":"Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission","startDateStruct":{"date":"2007-03"},"conditions":["B-cell Childhood Acute Lymphoblastic Leukemia","Childhood Acute Lymphoblastic Leukemia in Remission","Graft Versus Host Disease","L1 Childhood Acute Lymphoblastic Leukemia","L2 Childhood Acute Lymphoblastic Leukemia","T-cell Childhood Acute Lymphoblastic Leukemia"],"count":146,"armGroups":[{"label":"Tacro-MTX/Sirolimus GVHD Prophylaxis Regimen","type":"EXPERIMENTAL","interventionNames":["Drug: thiotepa","Drug: cyclophosphamide","Drug: tacrolimus","Drug: methotrexate","Drug: sirolimus","Radiation: total body irradiation"]},{"label":"Tacro-MTX GVHD Prophylaxis","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: thiotepa","Drug: cyclophosphamide","Drug: tacrolimus","Drug: methotrexate","Radiation: total body irradiation"]}],"interventions":[{"name":"thiotepa","otherNames":["Oncotiotepa","STEPA","TESPA","Tespamin","TSPA"]},{"name":"cyclophosphamide","otherNames":["CPM","CTX","Cytoxan","Endoxan","Endoxana"]},{"name":"tacrolimus","otherNames":["FK 506","Prograf"]},{"name":"methotrexate","otherNames":["amethopterin","Folex","methylaminopterin","Mexate","MTX"]},{"name":"sirolimus","otherNames":["AY 22989","Rapamune","rapamycin","SLM"]},{"name":"total body irradiation","otherNames":["TBI"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed acute lymphoblastic leukemia (ALL) in second complete remission (CR2) (M1 bone marrow, \\< 5% blasts by morphology) meeting the following criteria:\n\n  * Intermediate risk relapsed ALL in CR2 (may receive matched sibling transplantation only) meeting 1 of the following criteria:\n\n    * B-lineage ALL in CR2 after a late first bone marrow (BM) relapse (≥ 36 months after the initiation of primary chemotherapy) with or without associated extramedullary disease\n    * B-lineage ALL in CR2 after a very early isolated extramedullary relapse (\\<18 months from the initiation of primary chemotherapy)\n  * High risk relapsed ALL in CR2 (may receive other related donor, unrelated donor, or matched sibling transplantation) meeting 1 of the following criteria:\n\n    * In CR2 after an early first BM relapse (\\< 36 months from initiation of primary chemotherapy)\n    * T-lineage ALL in CR2 after a first BM relapse occurring at any time after initiation of primary chemotherapy\n    * Philadelphia chromosome-positive ALL in CR2 after a first BM relapse occurring at any time after the initiation of primary chemotherapy\n    * T-lineage ALL in CR2 after a very early isolated extramedullary relapse (\\<18 months from the initiation of primary chemotherapy)\n  * High risk de novo ALL in CR1 (may receive matched sibling, other related/unrelated BM/PBSC or unrelated CB transplantation) meeting 1 of the following criteria:\n\n    * Patients with the presence of t(9;22) translocation (Ph+) detected by cytogenetic or PCR analysis at initial diagnosis. For patients on AALL0622, the criteria for transplant are 1) any patient with Ph+ ALL with an available matched sibling donor or 2) any patient with Ph+ ALL that is defined as high risk (MRD \\> 1% Day 29 or MRD \\> 0.01% end-Consolidation Block 2) with any available donor, related or unrelated. Patients enrolled on AALL0622 are only eligible if they follow this algorithm.\n    * Patients with the presence of extreme hypodiploidy (\\< 44 chromosomes or DNA index of \\< 0.81) detected by cytogenetic/ploidy analysis at initial diagnosis.\n    * Patients with the presence of 11q23 (MLL) rearrangements detected by cytogenetic or PCR analysis at initial diagnosis who are slow early responders (M2/M3 at Day 14 or MRD \\> 0.1% at Day 29).\n* Enrolled on an appropriate COG relapsed ALL clinical trial after completing the required study therapy (i.e., minimum 1 re-induction course (4-6 weeks) and 1 round of intensive consolidation chemotherapy (3-6 weeks). Patients with high risk ALL in CR1 are eligible as soon as they have achieved a CR.\n\n  * Patients not on a COG relapsed ALL clinical trial are eligible provided they have received ≥ 1 round of re-induction lasting 4-6 weeks and 1 round of intensive consolidation chemotherapy lasting 3-6 weeks\n* No B-cell ALL L3 morphology with evidence of myc translocation by molecular or cytogenetic technique\n* No Down syndrome\n* No evidence of active CNS or other extramedullary disease (i.e., no CNS2)\n* Karnofsky performance status (PS) 60-100% (for patients \\> 16 years of age) OR Lansky PS 60-100% (for patients ≤ 16 years of age)\n* Shortening fraction ≥ 27% by echocardiogram OR ejection fraction ≥ 50% by radionuclide angiogram\n* ALT or AST \\< 5 times upper limit of normal\n* Bilirubin \\< 2.5 mg/dL (unless an increase is attributable to Gilbert's syndrome)\n* Creatinine clearance OR radioisotope glomerular filtration rate ≥ 70 mL/min\n* FEV\\_1 ≥ 60% by pulmonary function tests (PFTs)\n* FVC ≥ 60% by PFTs\n* DLCO ≥ 60% by PFTs\n* For children who are unable to cooperate for PFTs all of the following criteria must be met:\n\n  * No evidence of dyspnea at rest\n  * No exercise intolerance\n  * No requirement for supplemental oxygen therapy\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No HIV or uncontrolled fungal, bacterial, or viral infection\n\n  * Fungal infection acquired during induction therapy allowed provided there is a significant response to antifungal therapy with minimal or no evidence of disease by CT scan\n* Other concurrent immunosuppressants allowed\n* No prior allogeneic or autologous stem cell transplantation\n* No prior or concurrent voriconazole unless prior voriconazole therapy is completed or a different agent is substituted for voriconazole prior to study entry\n* No concurrent grapefruit juice during sirolimus administration","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"21 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Estimated Percentage of Participants With Event Free Survival","description":"An event is defined as relapse or transplant-related mortality. Relapse is defined in section 3.3 study protocol.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Relapses","description":"An event is defined as relapse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"Estimated Transplant Related Mortality Percentage","description":"Death in a patient who had not relapsed after transplant is defined as transplant-related mortality event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Estimated Rate of Acute Graft VS Host Disease (GVHD)","description":"Any grade acute graft vs host disease (defined in APPENDIX II study protocol).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]}]},{"type":"SECONDARY","title":"Estimated Rate of Overall Chronic Graft VS Host Disease","description":"Chronic graft vs host disease is defined in APPENDIX III of study protocol.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Relative Contribution of Resistance by Acute Lymphoblastic Leukemia (ALL) Blasts to Cytolytic Therapy (e.g., Chemotherapy/Irradiation) as a Cause of Relapse Post-transplantation","description":"An event is defined as relapse or transplant-related mortality.","classes":[]},{"type":"SECONDARY","title":"Relative Contribution of ALL Blasts to the Donor Immune Response as a Cause of Relapse Post Transplantation (Correlating Development of aGVHD With Relapse)","description":"An event is defined as relapse; estimated probability of relapse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Relative Contribution of ALL Blasts to the Donor Immune Response as a Cause of Relapse Pre-Transplantation (MRD)","description":"An event is defined as relapse; relapse risk is reported. Not able to be performed given the low numbers of blast samples available.","classes":[]},{"type":"SECONDARY","title":"Chimerism","description":"Evaluate the relative contribution of resistance by ALL blasts to the donor immune response as a cause of relapse post transplantation.","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":72},"commonTop":["White blood cell decreased","Neutrophil count decreased","Platelet count decreased","Lymphocyte count decreased","Hypokalemia"]}}}